Intelligent Bio Solutions Inc.
NasdaqCM INBS
Intelligent Bio Solutions Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2024: USD 1.22 M
-
Intelligent Bio Solutions Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 559.00 K, a 79.56% change year over year.
-
Intelligent Bio Solutions Inc. Gross Profit for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 311.32 K.
| Date | Gross Profit | Operating Income | EBIT | EBITDA |
|---|
Don’t Miss A Beat
| CEO | Mr. Harry Simeonidis |
| IPO Date | Dec. 23, 2020 |
| Location | United States |
| Headquarters | 142 West 57th Street |
| Employees | 50 |
| Sector | Healthcare |
| Industries | |
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Past 5 years
StockViz Staff
February 4, 2025
Any question? Send us an email